RxDoctor Payments Data

Cynthia Marengo

Gerontology · Inverness, FLNPI 1255821088

Payments from drug & device makers

$4,023in general payments, 2019–2025

Across 186 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alpha Cognition USA, Inc.$934
  • Acadia Pharmaceuticals Inc$875
  • Neurocrine Biosciences, Inc.$820
  • Teva Pharmaceuticals USA, Inc.$797
  • Avanir Pharmaceuticals, Inc.$352
  • Otsuka America Pharmaceutical, Inc.$137
  • plus $107 from 3 others

What the payments were for

  • Food & beverage$3,91197%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,023 in reported general payments places this provider in the 85th percentile of 714 gerontology providers in Florida.

See all gerontology providers in Florida

Medicare billing

Part B allowed, 2024
$100,651
Medicare patients
464
Services billed
1,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate82$601,878
NuplazidPimavanserin Tartrate113$584,937
NuedextaDextromethorphan Hbr/Quinidine232$350,551
Austedo XrDeutetrabenazine18$123,072
SecuadoAsenapine79$118,877
RexultiBrexpiprazole11$16,342
Divalproex Sodium181$12,305
Aripiprazole21$6,656
Trazodone Hcl303$4,649
Duloxetine Hcl71$4,576
Lorazepam276$4,496
Quetiapine Fumarate94$3,742
Mirtazapine87$3,193
Risperidone ErRisperidone Microspheres16$2,457
Sertraline Hcl129$1,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$820$601,87882 claims
Acadia Pharmaceuticals IncNuplazid$875$584,937113 claims
Avanir Pharmaceuticals, Inc.Nuedexta$352$350,551232 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$797$123,07218 claims
Otsuka America Pharmaceutical, Inc.Rexulti$137$16,34211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 714 gerontology providers in Florida.

Other gerontology in Inverness

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →